
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Microbiol. , 06 November 2023
Sec. Infectious Agents and Disease
Volume 14 - 2023 | https://doi.org/10.3389/fmicb.2023.1322004
This article is part of the Research Topic New Insights in Prosthetic Joint Infections View all 8 articles
This article is a correction to:
Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora
by Long, J., Gong, J., Zhu, H., Liu, X., Li, L., Chen, B., Ren, H., Liu, C., Lu, H., Zhang, J., and Wang, B. (2023). Front. Microbiol. 14:1232180. doi: 10.3389/fmicb.2023.1232180
In the published article, there was an error in Figure 4. The horizontal axis previously stated, “White ball ratio” which should be corrected as follows: “Albumin-globulin ratio”. The corrected Figure appears below.
Figure 4. Effect size (adoniss R2) of metadata on microbiota was calculated using the adonis2 function in the vegan package with 999 permutations.
In the published article, there was an error in the Results subsection 5.2, page 3. “Differences in gut microbiota between Phase 1 and Phase 2 in No-NAs group CHB patients”.
“The results of species accumulation curves and the Venn plot (Figure 1A) revealed that 31 and 118 ASVs were independently present in Phase 1 and Phase 2 subgroups, respectively.”
The corrected sentence appears below:
“The results of species accumulation curves and the Venn plot (Figure 1A) revealed that 31 and 110 ASVs were independently present in Phase 1 and Phase 2 subgroups, respectively.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: hepatitis B virus, HBeAg, HBsAg, tenofovir alafenamide, gut microbiota
Citation: Long J, Gong J, Zhu H, Liu X, Li L, Chen B, Ren H, Liu C, Lu H, Zhang J and Wang B (2023) Corrigendum: Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora. Front. Microbiol. 14:1322004. doi: 10.3389/fmicb.2023.1322004
Received: 15 October 2023; Accepted: 25 October 2023;
Published: 06 November 2023.
Edited and reviewed by: George Grant, University of Aberdeen, United Kingdom
Copyright © 2023 Long, Gong, Zhu, Liu, Li, Chen, Ren, Liu, Lu, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Huiping Lu, bGhwMzEwQDEyNi5jb20=; Jiming Zhang, am16aGFuZ0BmdWRhbi5lZHUuY24=; Bin Wang, d2FuZ2JpbkBodWFzaGFuLm9yZy5jbg==
†These authors have contributed equally to this work
‡ORCID: Bin Wang orcid.org/0000-0003-1067-7683
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.